Journal: Bioactive Materials

Article Title: Translational selenium nanoparticles trigger apoptosis in triple-negative breast cancer cells through the MAPKs/Bcl2 pathway

doi: 10.1016/j.bioactmat.2026.02.027

Figure Lengend Snippet: Schematic illustration of PTR-SeNPs and MUC1@PTR-SeNPs synthesis and their anti-tumor efficacy against human triple-negative breast cancer.

Article Snippet: Anti-human MUC1 therapeutic antibody Fab fragment (7B8) were purchased From Creative Biolabs (TAB-423MZ-F, USA).

Techniques:

Journal: Bioactive Materials

Article Title: Translational selenium nanoparticles trigger apoptosis in triple-negative breast cancer cells through the MAPKs/Bcl2 pathway

doi: 10.1016/j.bioactmat.2026.02.027

Figure Lengend Snippet: Structure characterization of PTR-SeNPs and MUC1@ PTR-SeNPs. Structure characterization of PTR-SeNPs by (A) TEM, (B) Zetasizer Nano ZS, (C, D) Nanosight NS300, (E1-4) HRTEM-EDS and (F, G) FT-IR. (H) Confirmation of MUC1-C + PTR-SeNPs conjugation by confocal microscopy after fluorescent labeling with anti-mouse IgG (H + L). (I, J) Characterization results of the particle size and potential of MUC1@PTR-SeNPs

Article Snippet: Anti-human MUC1 therapeutic antibody Fab fragment (7B8) were purchased From Creative Biolabs (TAB-423MZ-F, USA).

Techniques: Conjugation Assay, Confocal Microscopy, Labeling

Journal: Bioactive Materials

Article Title: Translational selenium nanoparticles trigger apoptosis in triple-negative breast cancer cells through the MAPKs/Bcl2 pathway

doi: 10.1016/j.bioactmat.2026.02.027

Figure Lengend Snippet: In vitro anti-tumor efficacy of PTR-SeNPs and MUC1@PTR-SeNPs on 17 TNBC c ell lines. ( A, B ) Protein expression level of MUC1 in 17 different TNBC cell lines. ( C, D ) IC 50 and maximum % growth inhibition of PTR-SeNPs and MUC1@PTR-SeNPs on 17 TNBC cell lines. ( E, G ) Cell cycle distribution triggered by PTR-SeNPs and MUC1@PTR-SeNPs in HCC1937 and MDA-MB-436 cells. After treatment with PTR-SeNPs or MUC1@PTR-SeNPs (4 and 40 μM) in HCC1937 and MDA-MB-436 cells for 72 h, cells were stained with propidium iodide followed by flow cytometry analysis using MultiCycle software. The apoptotic cell death was quantified by measuring the sub-G1 cell population. ( F, H ) Phosphatidylserine translocation mediated by PTR-SeNPs and MUC1@PTR-SeNPs in HCC1937 and MDA-MB-436 cells. After treatment with MUC1@PTR-SeNPs (4 and 40 μM) for 48 h, cells were co-stained with propidium iodide and Annexin-V-FITC followed by flow cytometry analysis [early apoptotic subset: Annexin V+/PI- (green); late apoptotic subset: Annexin V+/PT+ (red)].

Article Snippet: Anti-human MUC1 therapeutic antibody Fab fragment (7B8) were purchased From Creative Biolabs (TAB-423MZ-F, USA).

Techniques: In Vitro, Expressing, Inhibition, Staining, Flow Cytometry, Software, Translocation Assay

Journal: Bioactive Materials

Article Title: Translational selenium nanoparticles trigger apoptosis in triple-negative breast cancer cells through the MAPKs/Bcl2 pathway

doi: 10.1016/j.bioactmat.2026.02.027

Figure Lengend Snippet: In vivo anti-tumor efficacy of MUC1@PTR- SeNPs. (A) MUC1 mRNA expression in normal tissue and primary breast cancer tumor using GEPIA database. ( B ) MUC1 expression in tumor tissues of MDA-MB-468-bearing mice in preliminary study. (C – E) Dose-dependent study of tumor inhibition effect of MUC1@PTR-SeNPs [75 (Low), 375 (Mid) & 750 μg (High) Se/kg BW/day] on BALB/c nude mice transplanted with MDA-MB-468 xenograft after oral administration for 30 days. PTR-SeNPs (High; 750 μg Se/kg BW/day) was used to investigate the possible improvement of in vivo anti-tumor efficacy by the MUC1@PTR-SeNPs. Quantitative analysis of Se content (μg/g) in (F) blood and (G) tumor tissue of experimental mice. (H) H&E, Ki67 and Tunnel fluorescence staining of tumor sections to detect apoptosis in vivo . (I) Western blot analysis of PARP, p-Bcl-2, Bax and C-caspase-9 protein expression in tumor sections. (J) In the serum of each group of tumor-bearing mice, the results of blood biochemistry-related indexes were analyzed.

Article Snippet: Anti-human MUC1 therapeutic antibody Fab fragment (7B8) were purchased From Creative Biolabs (TAB-423MZ-F, USA).

Techniques: In Vivo, Expressing, Inhibition, Fluorescence, Staining, Western Blot